- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00585481
Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children
Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children - BREVI (Brazilian Respiratory Virus in Premature Infants) Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
PR
-
Curitiba, PR, Brazil, 80060-900
- Site Ref # / Investigator 6185
-
-
SP
-
Ribeirao Preto, SP, Brazil, 14049-900
- Site Ref # / Investigator 6189
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female infants that were born <35 weeks gestational age
The inclusion must be done during the following period:
- 24 hours prior confirmed maternity hospital discharge date, or
- Up to 72 hours after documented maternity hospital discharge date. In this case, RSV rapid test must be performed and subjects should be enrolled only if the results is negative.
- Less than 6 months of age at screening
- Born into or transferred to a participating hospital
- Able to receive follow-up medical care at the participating site and provide information during the follow-up period
- The legal representative is capable of understanding and complying with parameters as outlined in the protocol and able and willing to participate in this study, by signing the informed consent approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), after all the aspects of the study that might be relevant for his/her decision to participate are explained and all his/her questions and doubts are elucidated, and prior to the initiation of any screening or study-specific procedures.
Exclusion Criteria:
- RSV infection prior inclusion.
- Receipt of palivizumab or other immunoglobulin preparation containing RSV specific antibodies (i.e. RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella-zoster hyperimmunoglobulin)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
All subjects will perform samples collection for RSV analysis.
Subject's enrolled in Porto Alegre's site will perform lung function tests.
|
At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood). Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment.
Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis.
First measurement will be performed up to Visit 6 and repeated at Termination Visit.
Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the incidence of severe RSV LRTI requiring hospitalization among infants born <35 weeks gestational age for one year.
Time Frame: 1 Year
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the risk and protective factors for severe RSV LRTI in preterm Brazilian infants.
Time Frame: 1 Year
|
1 Year
|
To describe the seasonality of RSV infection in three cities in Brazil.
Time Frame: 1 Year
|
1 Year
|
To compare the incidence of wheezing episodes by 12 months after maternity hospital discharge among children with and without RSV LRTI.
Time Frame: 1 Year
|
1 Year
|
To evaluate the difference in lung function among children with and without RSV LRTI within the first year after maternity hospital discharge. Only children enrolled at one participating site will be evaluated with lung function analysis.
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Lino Rodrigues, MD, Abbott Laboratórios do Brasil Ltda.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A07-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Viruses
-
NovavaxCompleted
-
PfizerCompletedRespiratory Syncytial VirusesBelgium
-
Janssen Vaccines & Prevention B.V.CompletedRespiratory Tract Diseases | Respiratory Syncytial VirusesUnited States
-
Merck Sharp & Dohme LLCCompletedRespiratory Syncytial VirusesUnited Kingdom
-
Janssen Research & Development, LLCTerminatedRespiratory Syncytial VirusesAustralia, France, United Kingdom, Belgium, Taiwan, United States, Spain, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sweden, Korea, Republic of, Canada, Netherlands, Brazil, Germany, Poland
-
Janssen Research & Development, LLCTerminatedRespiratory Syncytial VirusesUnited States, Belgium, Canada, Hungary, Japan, Poland
-
Crucell Holland BVCompletedRespiratory Tract Infections | Respiratory Syncytial VirusesUnited States
-
Janssen Research & Development, LLCCompletedRespiratory Syncytial VirusesTaiwan, Belgium, United Kingdom, Argentina, Panama
-
Janssen Vaccines & Prevention B.V.CompletedRespiratory Tract Infections | Respiratory Syncytial VirusesUnited Kingdom, Finland, United States
-
PfizerKaiser PermanenteActive, not recruitingRespiratory Syncytial VirusesUnited States
Clinical Trials on Samples collection for viral diagnosis
-
Jules Bordet InstituteBristol-Myers Squibb; La Fondation contre le cancer, Belgique; Les Amis de l'Institut... and other collaboratorsRecruitingCNS MetastasesBelgium, France, Luxembourg
-
Ela ShaiCompletedInherited Platelet DisordersIsrael
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
Stanford UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Enrolling by invitationLymphoma | Hematologic Diseases | LeukemiaUnited States
-
NYU Langone HealthCompletedPulmonary TBUnited States
-
Innovaderm Research Inc.RecruitingPlaque Psoriasis | Atopic Dermatitis | Hidradenitis Suppurativa | Palmoplantar Pustulosis | Acne | Chronic Hand EczemaCanada
-
Centre Hospitalier Universitaire de NiceCompletedUrinary Tract InfectionsFrance
-
Rennes University HospitalCompletedAcute Respiratory Distress Syndrome | SARS-CoV-2 CoronavirusFrance
-
Centre Oscar LambretInstitut de Biologie de LilleTerminatedMelanoma | Kidney Neoplasms | Carcinoma, Hepatocellular | Colorectal NeoplasmsFrance
-
Assistance Publique - Hôpitaux de ParisFonds IMMUNOVCompleted